Table 5

Percentages of patients achieving a best response of VGPR or better to lenalidomide-bortezomib-dexamethasone and estimated 18-month PFS rates after lenalidomide-bortezomib-dexamethasone with/without ASCT, according to disease stage, baseline β2-microglobulin, baseline albumin, and presence of baseline cytogenetic abnormalities

Characteristic/valuenResponse of VGPR or better, n (%)Estimated 18-month PFS, % (95% CI)
Baseline characteristic    
    ISS disease stage    
        I 29 21 (72) 89 (70-96) 
        II/III 37 23 (62) 65 (47-78) 
    Durie-Salmon disease stage    
        I 22 12 (55) 82 (59-93) 
        II/III 44 32 (73) 72 (56-83) 
    β2-microglobulin, mg/L    
        < 3.5 44 32 (73) 77 (61-87) 
        ≥ 3.5 22 12 (55) 73 (49-87) 
    Albumin, g/dL    
        < 3.5 24 17 (71) 63 (40-78) 
        ≥ 3.5 42 27 (64) 83 (67-91) 
Cytogenetics present    
    Abnormal metaphase cytogenetics    
        Yes 5 (83) 83 (27-97) 
        No 60 39 (65) 75 (62-84) 
    Del 13/13q by FISH    
        Yes 24 18 (75) 79 (57-91) 
        No 27 16 (59) 65 (43-80) 
    Del 17p by FISH    
        Yes 3 (60) 100 
        No 45 30 (67) 68 (52-80) 
    t(4;14) by FISH    
        Yes 2 (100) 100 
        No 39 24 (62) 63 (46-77) 
    t(11;14) by FISH    
        Yes 11 7 (64) 73 (37-90) 
        No 40 28 (70) 72 (55-83) 
    Del 17p and/or t(4;14) by FISH    
        Yes 4 (67) 100 
        No 44 29 (66) 68 (51-79) 
Characteristic/valuenResponse of VGPR or better, n (%)Estimated 18-month PFS, % (95% CI)
Baseline characteristic    
    ISS disease stage    
        I 29 21 (72) 89 (70-96) 
        II/III 37 23 (62) 65 (47-78) 
    Durie-Salmon disease stage    
        I 22 12 (55) 82 (59-93) 
        II/III 44 32 (73) 72 (56-83) 
    β2-microglobulin, mg/L    
        < 3.5 44 32 (73) 77 (61-87) 
        ≥ 3.5 22 12 (55) 73 (49-87) 
    Albumin, g/dL    
        < 3.5 24 17 (71) 63 (40-78) 
        ≥ 3.5 42 27 (64) 83 (67-91) 
Cytogenetics present    
    Abnormal metaphase cytogenetics    
        Yes 5 (83) 83 (27-97) 
        No 60 39 (65) 75 (62-84) 
    Del 13/13q by FISH    
        Yes 24 18 (75) 79 (57-91) 
        No 27 16 (59) 65 (43-80) 
    Del 17p by FISH    
        Yes 3 (60) 100 
        No 45 30 (67) 68 (52-80) 
    t(4;14) by FISH    
        Yes 2 (100) 100 
        No 39 24 (62) 63 (46-77) 
    t(11;14) by FISH    
        Yes 11 7 (64) 73 (37-90) 
        No 40 28 (70) 72 (55-83) 
    Del 17p and/or t(4;14) by FISH    
        Yes 4 (67) 100 
        No 44 29 (66) 68 (51-79) 

FISH indicates fluorescence in situ hybridization; ISS, International Staging System; PFS, progression-free survival after lenalidomide-bortezomib-dexamethasone with/without transplantation; and VGPR, very good partial response.

or Create an Account

Close Modal
Close Modal